LIVER FIBROSIS TREATMENT MARKET ANALYSIS

Liver Fibrosis Treatment Market, by Treatment Type (Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist, ACE Inhibitors, Hepatotropic Drug, and Others), by Condition (Chronic Liver Diseases, Hepatitis C, and Nonalcoholic Steatohepatitis), by Distribution Channel (Hospitals, Specialty Clinics, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Aug 2022
Code : CMI2320
Pages :168
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Key players in the liver fibrosis treatment market are engaged in pre-clinical and clinical studies to develop novel treatment therapies in liver fibrosis regime, which is expected to drive the market growth over the forecast period.

Increasing research and development activities by key players in pre-clinical and clinical studies to develop novel treatment therapies in liver fibrosis regime is expected to drive the global liver fibrosis treatment market growth. For instance, in March 2018, the U.S. Food and Drug administration granted Orphan Drug Designation for PTG-300: a subcutaneous injectable developed by Protagonist Therapeutics, Inc. The PTG-300 is currently in clinical development stage for the potential treatment of beta-thalassemia, and can also be used in the liver fibrosis treatment. Furthermore, Gilead Sciences, Inc., a biopharmaceutical company, in October 2017, released the Phase II result studies for Selonsertib: GS-0976 in Nonalcoholic Steatohepatitis (NASH) stage F3 liver fibrosis. These studies reported that, GS-0976 led to significant reductions in concentration of liver fat and fibrosis. Moreover, Gilead Sciences also possesses 18 other pipeline molecules in the liver fibrosis treatment, which is further expected to boost company’s revenue in 2025.